medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2023, Number 3

<< Back Next >>

Medicina & Laboratorio 2023; 27 (3)

Intrinsic subtypes of breast cancer and prognostic factors in a reference center in Medellin, Colombia. A descriptive study

Evilla-Olmos JM, Álvarez-Beltrán WA, Velásquez-García Y, Garrido-Zea EF, Escudero-Cardona DE, Bonilla-Sepúlveda OA

Language: Spanish
References: 28
Page: 199-209
PDF size: 109.79 Kb.


ABSTRACT

Introduction. Among women, breast cancer is the most common cancer in the world. It represents a heterogeneous disease, because the same histopathological type can have different biological behavior according to its molecular classification, providing prognostic value and as a predictor of response to neoadjuvant chemotherapy. The objective of this study was to describe the distribution of intrinsic subtypes of breast cancer, and their association with prognostic factors, as well as the sociodemographic and clinical characteristics of patients at the Clínica Medellín, between 2016 and 2019. Methodology. Descriptive, retrospective study of an institutional database, in the period 2016 to 2019. Demographic and clinical data from medical records were analyzed using descriptive statistics. Results. A total of 468 medical records were included in the study, the median age at diagnosis was 61 years, and 27% (n=131) were under 50 years of age. The most frequent histological type was ductal with 89.1% (n=417), and histological grade 2 was the most frequent with 44% (n=206) of the cases. The most frequent intrinsic subtype was luminal A with 32.7% (n=153), followed by luminal B HER2- with 30.1% (n=141), luminal B HER2+ with 17.3% (n=81), triple negative with 13% (n=61) and, finally, HER2 enriched with 6.8% (n=32). Conclusion. The distribution of the intrinsic subtypes of breast cancer in the study population showed that the luminal A subtype was the most frequent, while the triple negative and HER2-enriched subtypes were the least frequent.


REFERENCES

  1. Global Cancer Observatory-WHO. Estimatednumber of new cases in 2020, worldwide,females, all ages. Lyon, France: Cancer today,IARC; 2023. Acceso 15 de marzo de 2023.Disponible en https://gco.iarc.fr/today/onlineanalysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0.

  2. Ministerio de Salud y Protección Social(Minsalud), Dirección de Epidemiología yDemografía, Cooperación Bloomberg-VitalStrategies. Mortalidad en Colombia periodo2020-2021. Medición de la mortalidad por todaslas causas y COVID-19. 2022. Acceso 10de marzo de 2023. Disponible en https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/mortalidad-colombiaperiodo-2020-2021.pdf.

  3. Organización Mundial de la Salud (OMS).Cáncer de mama. Ginebra, Suiza: OMS; 2021.Acceso 11 de marzo de 2023. Disponibleen https://www.who.int/es/news-room/factsheets/detail/breast-cancer.

  4. American Joint Committee on Cancer(AJCC). Cancer staging manual: Breast cancer.Amin MB, Edge SB, Greene FL, Eds. 8th ed. Chicago,IL, USA: Springer; 2018.

  5. Perou CM, Sørlie T, Eisen MB, van de Rijn M,Jeffrey SS, Rees CA, et al. Molecular portraits ofhuman breast tumours. Nature 2000;406:747-752. https://doi.org/10.1038/35021093.

  6. Arrechea-Irigoyen MA, Vicente-García F,Córdoba-Iturriagagoitia A, Ibáñez-BeroizB, Santamaría-Martínez M, Guillén-GrimaF. Subtipos moleculares del cáncer de mama:implicaciones pronósticas y característicasclínicas e inmunohistoquímicas. Anales SisSan Navarra 2011;34:219-233. https://doi.org/10.4321/S1137-66272011000200008

  7. Park S, Koo JS, Kim MS, Park HS, Lee JS, LeeJS, et al. Characteristics and outcomes accordingto molecular subtypes of breast cancer asclassified by a panel of four biomarkers usingimmunohistochemistry. Breast 2012;21:50-57.https://doi.org/10.1016/j.breast.2011.07.008.

  8. Lips EH, Mulder L, de Ronde JJ, MandjesIA, Koolen BB, Wessels LF, et al. Breast can-cer subtyping by immunohistochemistry andhistological grade outperforms breast cancerintrinsic subtypes in predicting neoadjuvantchemotherapy response. Breast Cancer ResTreat 2013;140:63-71. https://doi.org/10.1007/s10549-013-2620-0.

  9. Burstein HJ, Curigliano G, Thürlimann B, WeberWP, Poortmans P, Regan MM, et al. Customizinglocal and systemic therapies for womenwith early breast cancer: the St. Gallen InternationalConsensus Guidelines for treatmentof early breast cancer 2021. Ann Oncol2021;32:1216-1235. https://doi.org/10.1016/j.annonc.2021.06.023.

  10. Voduc KD, Cheang MC, Tyldesley S, GelmonK, Nielsen TO, Kennecke H. Breast cancer subtypesand the risk of local and regional relapse.J Clin Oncol 2010;28:1684-1691. https://doi.org/10.1200/jco.2009.24.9284.

  11. Parker JS, Mullins M, Cheang MC, Leung S,Voduc D, Vickery T, et al. Supervised risk predictorof breast cancer based on intrinsic subtypes.J Clin Oncol 2009;27:1160-1167. https://doi.org/10.1200/jco.2008.18.1370.

  12. Prat A, Carey LA, Adamo B, Vidal M, TaberneroJ, Cortés J, et al. Molecular featuresand survival outcomes of the intrinsic subtypeswithin HER2-positive breast cancer. JNatl Cancer Inst 2014;106:dju152. https://doi.org/10.1093/jnci/dju152.

  13. Maisonneuve P, Disalvatore D, Rotmensz N,Curigliano G, Colleoni M, Dellapasqua S, etal. Proposed new clinicopathological surrogatedefinitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.Breast Cancer Res 2014;16:R65. https://doi.org/10.1186/bcr3679.

  14. Focke CM, van Diest PJ, Decker T. St Gallen2015 subtyping of luminal breast cancers:impact of different Ki67-based proliferationassessment methods. Breast Cancer Res Treat2016;159:257-263. https://doi.org/10.1007/s10549-016-3950-5.

  15. Cheang MC, Martin M, Nielsen TO, Prat A,Voduc D, Rodriguez-Lescure A, et al. Definingbreast cancer intrinsic subtypes byquantitative receptor expression. Oncologist2015;20:474-482. https://doi.org/10.1634/theoncologist.2014-0372.

  16. Bloom HJ, Richardson WW. Histological gradingand prognosis in breast cancer; a study of1409 cases of which 359 have been followedfor 15 years. Br J Cancer 1957;11:359-377.https://doi.org/10.1038/bjc.1957.43.

  17. Reigosa A, Hardisson D, Sanz F, Caleiras E, SaldiviaF, Fernández Á. Subclasificación de los tiposmoleculares de cáncer de mama de acuerdoa la expresión de marcadores inmunohistoquímicosy evolución. Invest Clin 2016;57:187-216.

  18. Ossa-Gómez CA, Gómez-Wolff LR, Ascuntar-Tello J, García-García HI. Supervivenciaglobal y libre de enfermedad según subtipomolecular intrínseco en una cohorte de 2.200pacientes con cáncer de mama. Experienciade un centro colombiano. Rev Médica Sanitas2015;18:122-132.

  19. McGuire A, Brown JA, Malone C, McLaughlinR, Kerin MJ. Effects of age on the detectionand management of breast cancer. Cancers(Basel) 2015;7:908-929.

  20. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilitiesof death from breast cancer and othercauses among female breast cancer patients. JNatl Cancer Inst 2004;96:1311-1321. https://doi.org/10.1093/jnci/djh253.

  21. Hanby AM, Walker C, Tavassoli FA, Devilee P.Pathology and genetics: Tumours of the breastand female genital organs. WHO Classificationof tumours series-Volume IV. Lyon, France:IARC Press. Breast Cancer Res 2004;6:133.https://doi.org/10.1186/bcr788.

  22. Weigelt B, Horlings HM, Kreike B, HayesMM, Hauptmann M, Wessels LF, et al. Refinementof breast cancer classification by molecularcharacterization of histological specialtypes. J Pathol 2008;216:141-150. https://doi.org/10.1002/path.2407.

  23. Howlader N, Altekruse SF, Li CI, Chen VW,Clarke CA, Ries LA, et al. US incidence ofbreast cancer subtypes defined by joint hormonereceptor and HER2 status. J Natl CancerInst 2014;106:dju055. https://doi.org/10.1093/jnci/dju055.

  24. Bonilla-Sepúlveda OA, Matute-Turizo G, SevericheC. Clasificación en subtipos intrínsecosde los carcinomas de mama analizados enun centro de patología de Medellín en el año2011. CES Med 2015;29:36-45.

  25. Plasilova ML, Hayse B, Killelea BK, HorowitzNR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: Analysis of 38,813cases from the national cancer database. Medicine(Baltimore) 2016;95:e4614. https://doi.org/10.1097/md.0000000000004614.

  26. Newman LA, Reis-Filho JS, Morrow M, CareyLA, King TA. The 2014 Society of SurgicalOncology Susan G. Komen for the curesymposium: triple-negative breast cancer.Ann Surg Oncol 2015;22:874-882. https://doi.org/10.1245/s10434-014-4279-0.

  27. Wang DY, Jiang Z, Ben-David Y, WoodgettJR, Zacksenhaus E. Molecular stratificationwithin triple-negative breast cancersubtypes. Sci Rep 2019;9:19107. https://doi.org/10.1038/s41598-019-55710-w.

  28. Santonja A, Sánchez-Muñoz A, Lluch A,Chica-Parrado MR, Albanell J, ChacónJI, et al. Triple negative breast cancer subtypesand pathologic complete responserate to neoadjuvant chemotherapy. Oncotarget2018;9:26406-26416. https://doi.org/10.18632/oncotarget.25413.




2020     |     www.medigraphic.com